Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine

Frontiers in Genetics

Volumn 3, Issue FEB, 2013, Pages

  Lee, Su Jun ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

CYP2C19; Drug; Functional genetics; Personalized medicine; SNP

Indexed keywords

EID: 84875229240     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00318     Document Type: Review

References (71)

1. Andersson, T., Regardh, C. G., Lou, Y. C, Zhang, Y., Dahl, M. L., and Bertilsson, L. (1992). Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2, 25-31.
2. Babalola, C. P., Adejumo, O., Ung, D., Xu, Z., Odetunde, A., Kotila, T., et al. (2010). Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. J. Clin. Phartn. Ther. 35,471-477.
3. Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, L., Goldstein, J. A., et al. (1995). The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther. 57, 662-669.
4. Benhamou, S., Bouchardy, C, and Dayer, P. (1997). Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics 7, 157-159.
5. Berge, M., Guillemain, R., Tregouet, D. A., Amrein, C, Boussaud, V., Chevalier, P., et al. (2011). Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur. J. Clin. Pharmacol. 67, 253-260.
6. Bertilsson, L. (1995). Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29, 192-209.
7. Bouman, H. J., Schomig, E., van Werkum, J. W., Velder, J., Hackeng, C. M., Hirschhauser, C, et al. (2011). Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116.
8. Brandt, J. T., Close, S. L., Iturria, S. J., Payne, C. D., Farid, N. A., Ernest, C. S. II, et al. (2007). Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436.
9. Bravo-Villalta, H. V., Yamamoto, K., Nakamura, K., Baya, A., Okada, Y, and Horiuchi, R. (2005). Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol. 61, 179-184.
10. Chen, L., Qin, S., Xie, J., Tang, J., Yang, L, Shen, W., et al. (2008). Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9, 691-702.
11. Clarke, T. A., and Waskell, L. A. (2003). The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by ator-vastatin. Drug Metab. Dispos. 31, 53-59.
12. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., and Goldstein, J. A. (1994a). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598.
13. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., and Goldstein, J. A. (1994b). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422.
14. Desta, Z., Zhao, X., Shin, J. G., and Flockhart, D. A. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958.
15. Ferguson, R. J., De Morais, S. M., Ben-hamou, S., Bouchardy, C, Blaisdell, J., Ibeanu, G., et al. (1998). A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284, 356-361.
16. Funck-Brentano, C, Becquemont, L., Lenevu, A., Roux, A., Jaillon, P., and Beaune, P. (1997). Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J. Pharmacol. Exp. Ther. 280, 730-738.
17. Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., et al. (1998). Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129, 1027-1030.
18. Furuta, T., Shirai, N., Sugimoto, M., Ohashi, K., and Ishizaki, T. (2004). Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 5, 181-202.
19. Gaikovitch, E. A., Cascorbi, I., Mrozikiewicz, P. M., Brockmoller, J., Frotschl, R., Kopke, K., et al. (2003). Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 59,303-312.
20. Goldstein, J. A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355.
21. Goldstein, J. A., Ishizaki, T., Chiba, K., De Morais, S. M., Bell, D., Krahn, P. M., et al. (1997). Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64.
22. Hamdy, S. I., Hiratsuka, M., Nara-hara, K., El-Enany, M., Moursi, N., Ahmed, M. S., et al. (2002). Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 53, 596-603.
23. Hashemi-Soteh, S. M., Shahabi-Majd, N., Gholizadeh, A. R., and Shiran, M. R. (2012). Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran). Genet. Test. Mol. Biomarkers 16, 817-821.
24. Helsby, N. A., Watkins, W M., Mberu, E., and Ward, S. A. (1991). Inter-individual variation in the metabolic activation of the anti-malarial biguanides. Parasitol. Today 7, 120-123.
25. Hulot, J. S., Bura, A., Villard, E., Azizi, M., Remones, V., Goyenvalle, C, et al. (2006). Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247.
26. Ibeanu, G. C, Blaisdell, J., Ferguson, R. J., Ghanayem, B. I., Brosen, K., Benhamou, S., et al. (1999). A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290, 635-640.
27. Ibeanu, G. C, Blaisdell, J., Ghanayem, B I., Beyeler, C, Benhamou, S., Bouchardy, C, et al. (1998a). An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabo lizer phenotype in Caucasians. Pharmacogenetics 8, 129-135.
28. Ibeanu, G. C, Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C, Dayer, P., et al. (1998b). Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286, 1490-1495.
29. Ingelman-Sundberg, M., Sim, S. C, Gomez, A., and Rodriguez-Antona, C (2007). Influence of cytochrome P450 polymorphisms on drug ther apies: pharmacogenetic, pharma- coepigenetic and clinical aspects. Pharmacol. Ther. 116,496-526.
30. Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., and Brosen, K. (1996). Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51, 73-78.
31. Jose, R., Chandrasekaran, A., Sam, S. S., Gerard, N., Chanolean, S., Abraham, B. K., et al. (2005). CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam. Clin. Pharmacol. 19, 101-105.
32. Jung, F., Richardson, T. H., Raucy, J. L., and Johnson, E. F. (1997). Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab. Dispos. 25, 133-139.
33. Kaneko, A., Lum, J. K., Yaviong, L., Taka-hashi, N., Ishizaki, T., Bertilsson, L., et al. (1999). High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 9, 581-590.
34. Kearns, G. L., Leeder, J. S., and Gaedigk, A. (2010). Impact of the CYP2C19*17 allele on the pharma-cokinetics of omeprazole and pan-toprazole in children: evidence for a differential effect. Drug Metab. Dispos. 38, 894-897.
35. Kim, K. A., Song, W. K., Kim, K. R., and Park, J. Y. (2010). Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles./. Clin. Pharm. Ther. 35, 697-703.
36. Kubica, A., Kozinski, M., Grzesk, G., Fabiszak, T., Navarese, E. P., and Goch, A. (2011). Genetic determinants of platelet response to clopidogrel. J. Thromb. Thrombolysis ?>2, 459-466.
37. Kurzawski, M., Gawronska-Szklarz, B., Wrzesniewska, J., Siuda, A., Starzyn-ska, T., and Drozdzik, M. (2006). Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur. J. Clin. Pharmacol. 62, 877-880.
38. Lamba, J. K., Dhiman, R. K., and Kohli, K. K. (2000). CYP2C19 genetic mutations in North Indians. Clin. Pharmacol. Ther. 68, 328-335.
39. Lee, S. J., Kim, W Y, Kim, H., Shon, J. H., Lee, S. S., and Shin, J. G. (2009). Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab. Dispos. 37, 2262-2269.
40. Lee, S. S., Lee, S. J., Gwak, J., Jung, H. J., Thi-Le, H., Song, I. S., et al. (2007). Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther. Drug Monit. 29, 455-459.
41. Li, X. Q., Andersson, T. B., Ahlstrom, M., and Weidolf, L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lanso-prazole, pantoprazole, and rabepra-zole on human cytochrome P450 activities. Drug Metab. Dispos. 32, 821-827.
42. Luo, H. R., Poland, R. E., Lin, K. M., and Wan, Y. J. (2006). Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin. Pharmacol. Ther. 80, 33-40.
43. Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., et al. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. DrugMetab. Dispos. 31, 421-431.
44. Mankowski, D. C. (1999). The role of CYP2C19 in the metabolism of (±) bufuralol, the prototypic substrate of CYP2D6. DrugMetab. Dispos. 27, 1024-1028.
45. Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L, Hockett, R. D., Brandt, J. T., et al. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362.
46. Mills, D. C, Puri, R., Hu, C. J., Min-niti, C, Grana, G., Freedman, M. D., et al. (1992). Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arte-rioscler. Thromb. 12,430-436.
47. Morita, J., Kobayashi, K., Wanibuchi, A., Kimura, M., Irie, S., Ishizaki, T., et al. (2004). A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab. Pharmacokinet. 19, 236-238.
48. Myrand, S. P., Sekiguchi, K., Man, M. Z., Lin, X., Tzeng, R. Y, Teng, C. H., et al. (2008). Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84, 347-361.
49. Nielsen, K. K., Brosen, K., Hansen, M. G., and Gram, L. E (1994). Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin. Pharmacol. Ther. 55, 518-527.
50. Pedersen, R. S., Brasch-Andersen, C, Sim, S. C, Bergmann, T. K., Hailing, J., Petersen, M. S., et al. (2010). Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 66,1199-1205.
51. Qin, X. P., Xie, H. G., Wang, W., He, N., Huang, S. L, Xu, Z. H., et al. (1999). Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin. Pharmacol. Ther. 66, 642-646.
52. Ramsjo, M., Aklillu, E., Bohman, L., Ingelman-Sundberg, M., Roh, H. K., and Bertilsson, L. (2010). CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur. J. Clin. Pharmacol. 66, 871-877.
53. Richter, T., Murdter, T. E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., et al. (2004). Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308, 189-197.
54. Rudberg, I., Mohebi, B., Hermann, M., Refsum, H., and Molden, E. (2008). Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83, 322-327.
55. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L., Spina, E., and Ingelman-Sundberg, M. (2001). Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52,447-450.
56. Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., et al. (2010). Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121,512-518.
57. Sim, S. C, Risinger, C, Dahl, M. L, Aklillu, E., Christensen, M., Bertilsson, L., et al. (2006). A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antide-pressants. Clin. Pharmacol. Ther. 79, 103-113.
58. Sindrup, S. H., Brosen, K., Hansen, M. G., Aaes-Jorgensen, T., Overo, K. E, andGram.L.E (1993).Pharmacoki-netics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 15, 11-17.
59. Skjelbo, E., Brosen, K., Hallas, J., and Gram, L. E (1991). The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin. Pharmacol. Ther. 49,18-23.
60. /-hydroxylation phenotype status. Clin. Pharmacol. Ther. 61, 574-582.
61. Sugimoto, K., Uno, T., Yamazaki, H., and Tateishi, T. (2008). Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br. J. Clin. Pharmacol. 65, 437-439.
62. Tassaneeyakul, W., Mahatthana-trakul, W., Niwatananun, K., Na-Bangchang, K., Tawalee, A., Krikreangsak, N., et al. (2006). CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet. 21,286-290.
63. Tateishi, T., Kumai, T., Watanabe, M., Nakura, H., Tanaka, M., and Kobayashi, S. (1999). Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omepra-zole metabolism. Br. J. Clin. Pharmacol. 47, 454-457.
64. Tiroch, K. A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schomig, A., et al. (2010). Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart. J. 160, 506-512.
65. Wan, J., Xia, H., He, N., Lu, Y. Q., and Zhou, H. H. (1996). The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br. J. Clin. Pharmacol. 42, 471-474.
66. Ward, S. A., Helsby, N. A., Skjelbo, E., Brosen, K., Gram, L. F., and Brecken-ridge, A.M. (1991). The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br. J. Clin. Pharmacol. 31, 689-692.
67. Wilkinson, G. R., Guengerich, F. P., and Branch, R. A. (1989). Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43, 53-76.
68. Xiao, Z. S., Goldstein, J. A., Xie, H. G., Blaisdell, J., Wang, W, Jiang, C. H., et al. (1997). Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281, 604-609.
69. Xie, H. G., Kim, R. B., Wood, A. J., and Stein, C. M. (2001). Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol 41, 815-850.
70. Yao, C, Kunze, K. L., Trager, W. E, Kha-rasch, E. D., and Levy, R. H. (2003). Comparison of in vitro and in vivo inhibition potencies of fluvoxam-ine toward CYP2C19. Drug Metab. Dispos. 31, 565-571.
71. Zalloum, I., Hakooz, N., and Arafat, T. (2012). Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C 19*1 and CYP2C 19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol. Rep. 39, 4195-4200.